Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.47 USD
4.99%
Market Closed
Updated:
May 2, 2024
Editas Medicine Inc
Income from Continuing Operations
|
Editas Medicine Inc
Income from Continuing Operations Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Income from Continuing Operations
-$153.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$5.6B
|
CAGR 3-Years
298%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
See Also
What is Editas Medicine Inc's Income from Continuing Operations?
Income from Continuing Operations
-153.2m
USD
-153.2m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Income from Continuing Operations amounts to -153.2m USD.
What is Editas Medicine Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-7%
-7%
Over the last year, the Income from Continuing Operations growth was 30%. The average annual Income from Continuing Operations growth rates for Editas Medicine Inc have been -10% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
